A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04855201
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04837196
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸University of Iowa Hospitals, Iowa City, Iowa, United States
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04729114
- Locations
- 🇺🇸
Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸First Urology, Jeffersonville, Indiana, United States
🇺🇸Garden Sate Urology, Morristown, New Jersey, United States
A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04699877
- Locations
- 🇺🇸
Orange County Research Institute, Tustin, California, United States
🇺🇸National Institute of Clinical Research, Garden Grove, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
- Conditions
- Interventions
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04641975
- Locations
- 🇹🇷
Site TR90001, Bursa, Turkey
🇫🇷Site FR33001, Marseille, France
🇰🇷Site KR82001, Seoul, Seoul Teugbyeolsi, Korea, Republic of
A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04641260
- Locations
- 🇺🇸
Parexel, Baltimore, Maryland, United States
A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04482270
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸American Research Corporation, San Antonio, Texas, United States
A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04476849
- Locations
- 🇺🇸
Clinical Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸National Institute of Clinical Research, Garden Grove, California, United States
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants
- First Posted Date
- 2020-06-26
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04448561
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States
A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04447287
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States